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Abstract
Background: The role of methylation status of the thyroid stimulating hormone receptor gene (TSHr) in the
discrimination of benign and malignant thyroid nodules has already been studied using paraffin blocks and cell
lines. As cytological sampling plays an important role in assessment of thyroidal nodules, we have investigated the
potential clinical use of TSHr methylation status of fine needle aspiration specimens reported according to Bethesda
System.
Method: Sixty nine patients who had both cytological and pathological diagnosis of the same nodule were
selected. Four groups were composed according to cytological and pathological diagnoses: Benign (B), papillary
thyroid carcinoma (PTC), atypia of unknown significance (AUS) and follicular neoplasia (FN). The latter 2 groups
were further sub-classified into 2 as benign (AUS-B and FN-B) and malignant (AUS-M and FN-M) according to final
pathological diagnosis. DNAs were isolated from the fine needle aspiration cytology specimens and the
methylation status of TSHr promotor region was investigated by using methylation specific polymerase chain
reaction.
Results: Overall, TSHr methylation was present in 58 % of cases; 71 % of malignant and 46 % of benign nodules.
PTC group showed the highest TSHr methylation rate (87 %), followed by 61 % in AUS, 44 % in B, and 30 % in FN
(p = 0.016). TSHr methylation rate was significantly higher in PTC group when compared to B (p = 0.013) and FN-B
(p = 0.004) groups; but not in FN-M (p = 0.115) or AUS (p = 0.096) groups. All 9 cases of papillary thyroid carcinoma
with lymph node metastasis showed TSHr methylation. Positive predictive value, negative predictive value,
sensitivity and specificity of TSHr methylation in determination of malignancy were calculated as 60, 66, 71 and
54 %, respectively.
Conclusion: The eminent ratio of TSHr methylation in well-differentiated thyroid carcinoma against benign
thyroidal nodules adduced that TSHr methylation status can be utilized as a tumor marker for well-differentiated
thyroid cancer; however, it has a limited value. The determination of methylation status of TSHr gene had no
efficiency on decision of the malignant potential for the nodules which are cytologically classified as atypia of
undetermined significance.
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Background
Thyroid cancer is the most common endocrine malig-
nancy, comprising 90 % of endocrine cancer, although
it represents less than 1 % of all human cancer. The
most prevalent types of thyroid cancer are well differ-
entiated (papillary or follicular) thyroid carcinomas [1].
Introduction of fine needle aspiration cytology (FNAC)
has dramatically changed the surgical management of
the patients, and FNAC has become the most reliable
test for the diagnosis of the thyroid cancer. In order to
establish a good correlation between surgeon and
pathologists, the cytological information obtained from
FNAC is assembled into the 6 groups according to the
Bethesda System: 1) Non-diagnostic, 2) Benign, 3) Aty-
pia of Undetermined Significance or Follicular Lesion
of Undetermined Significance, 4) Follicular Neoplasm
or Suspicious for a Follicular Neoplasm, 5) Suspicious
for Malignancy and 6) Malignant [2]. Consequently, the
management of patients with FNAC resulted as “suspi-
cious for malignancy” or “follicular lesion” has arisen as
a contemporary issue in the treatment of thyroid can-
cer. Therefore, scientific efforts are directed to increase
diagnostic precision in the “atypia of undetermined sig-
nificance”and “follicular neoplasia” groups in order to
achieve a more reliable surgical management.
It is known that methylation of specific genes, which
silence the affected gene, plays an important role in the
pathogenesis of thyroid cancer as in any other type of can-
cers [3]. As thyroid stimulating hormone receptor is the
main hormone receptor responsible for growth and
physiological functioning of thyroid gland, methylation of
TSHr gene is believed to have an important role in the
development of thyroid cancer [4, 5]. In fact, there are
some studies about histological material of thyroid nod-
ules revealing the role of TSHr methylation in the thyroid
carcinogenesis [6–9]; however, data about the TSHr
methylation status in FNAC material is lacking.
In this study, we investigated the methylation status of
TSHr in well differentiated thyroid cancers using cytology
derived DNA, hence its potential role as a diagnostic test
in the discrimination of benign and malignant thyroid
nodules.
Methods
This study was approved by the ethics committee of
Hacettepe University. Study participants or their legal
guardians provided written informed consent.
Patient groups and cytological material
Eighty-eight patients, who had cytological diagnosis, surgi-
cal intervention and final pathological evaluation in our
center, were selected from 4355 consecutive patients, who
presented with thyroidal nodule between 2007 and 2011.
Vast majority of the FNAC in our institution was
performed under ultrasound guidance. FNAC material
was obtained from the archives; 19 patients were excluded
because of limited diagnostic cytological material. Slides
of remaining 69 patients were reviewed by two patholo-
gists (SO and KK). Cytological diagnoses were given by a
single pathologist (SO). Clinical features, thyroglobulin
levels, nodule size and the results of cytology and path-
ology reports were recorded using patient files and
computer-based patient data system. Only cytological
slides were used for the study, and 1 to 3 slides for each
case were selected regarding to the availability of the cyto-
logical specimen and cellularity.
According to cytology and pathology reports, 69 pa-
tients were classified into 4 groups: 1) Group “B”, patients
with benign FNAC treated surgically because of a thyroid
nodule greater than 3 cm, patient’s decision or cosmetic
purposes, and diagnosed as benign pathologically, 2)
Group “PTC”, patients with malignant FNAC and patho-
logically diagnosed as well-differentiated papillary thyroid
carcinoma, 3) Group “AUS”, patients diagnosed as atypia
of undetermined significance in FNAC, 4) Group “FN”,
patients evaluated as follicular neoplasm in FNAC. The
3rd and 4th groups were further divided into 2 subgroups
as benign (AUS-B and FN-B) and malignant (AUS-M and
FN-M) according to final pathological assessment. Patient
selection was supervised in order to have an equal number
in each group (Table 1).
TSHr methylation by methylation specific polymerase
chain reaction (MSP)
One hundred forty slides from 69 patients were
selected for DNA isolation. DNAs were isolated and
bi-sulfated using CpGenoma DNA Modification Kit
S7820 (Chemicon International Company, USA) ac-
cording to the manufacturer’s protocols. The sequence
of the primers used in the DNA amplification were
obtained from the study of Smith et al. [6]. 2.25 ng
from each of 3 % Dimethyl Sulfoxide (DMSO),
16.6 mM Ammonium Sulfate, 67 mM Tris- Borate-
EDTA buffer (Santa Cruz, USA, pH 8.8), 6.7 mM
MgCl2, 10 mM 2-Mercaptoethanol, 1.23 mM deoxynu-
cleotide triphosphates, sense and anti-sense DNA base
primers, 1 μl from bi-sulfite modified DNA and 0.5
units from DNA Taq polymerase (Invitrogen Comp.,
USA) were mixed for MSP.
The PCR conditions for the TSHr were as follows:
1 cycle at 95 °C for 15 min, 95 °C for 45 s, 61 °C for 45 s
and 72 °C for 1 min. This cycle was repeated for 40 times
followed by a final 10 min extension at 72 °C. Positive and
negative control DNA samples and controls without DNA
were used for each set of reactions. The final PCR prod-
ucts were resolved with agarose gel electrophoresis for 1 h
and stained with ethidium bromide for visualization
(Major Science, DI-01 model). Bands at 91 and 88 base
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pairs were regarded as references for unmethylated and
methylated TSHr, respectively (Fig. 1) [7].
Statistics
Patients’ variables were analyzed using SPSS 21.0. The
relationships in between categorical variables were ana-
lyzed by either Pearson chi-square or Fisher’s exact test.
Since the data did not meet the assumption of normal
distribution (by Kolmogorov-Smirnov test), the informa-
tion between two independent groups was analyzed with
the Mann–Whitney U-test or Kruskal-Wallis test. All
statistical inferences were two-tailed and p value <0.05
was considered to be statistically significant.
Results
Clinical information is summarized in Table 2. Fifty-nine
patients were female (85.5 %) and 10 were male (14.5 %).
Male to female ratio of B and AUS groups were lower
than that of PTC and FN groups, particularly of FN-B
group. The mean age was49 (range 26–80), and the age
was evenly distributed among groups. Mean diameter of
nodules was 23.0 ± 11.6 mm; B and FN groups had lar-
ger nodules than PTC and AUS groups (p = 0,001). Nine
patients in PTC group had at least 1 metastatic lymph
node. Thyroglobulin levels were not significantly differ-
ent among the groups (P = 0.326).
Overall TSHr methylation was positive in 58 % of
cases; 71 % of malignant nodules and 46 % of benign
nodules showed TSHr methylation (Fig. 1, p = 0.036).
Positive predictive value, negative predictive value, sensi-
tivity and specificity of TSHr methylation In FNAC ma-
terial in determination of malignancy were calculated as
60, 66, 71 and 54 %, respectively. There was no correl-
ation between TSHr methylation status and serum
thyroglobulin levels (p = 0.151), age (p = 0.162) or size of
the nodule (p = 0.892).
The highest rate of TSHr methylation was found in
the PTC group (13/15, 87 %), it was 44 % (7/16) in B,
61 % (17/28) in AUS and 30 % (3/10) in FN (p = 0.016,
Fig. 2). There were no cases of follicular adenomas
with a positive methylation status of TSHr(0/4)
whereas in 3 of 6 (50 %) follicular carcinomas TSHr’s
were found to be methylated. Papillary thyroid carcin-
omas (PTC group) significantly showed higher TSHr
methylation status than benign colloidal nodules (B
group, p = 0.013) and follicular adenomas (FN-B, p =
0.004) do; but no higher than in follicular carcinomas
(FN-M, p = 0.115) or in AUS (p = 0.096). In PTC
group, all 9 cases showing lymph node metastasis had
positive methylation status of TSHr. There was no
significant difference between subgroups of atypia of
unknown significance (p = 0.934). TSHr of follicular
Fig. 1 Elecrophoresis gel appearance of TSHr methylation status
Table 1 Patient groups
Groups FNAC Pathological Diagnosis n







AUS-B AUS Benign 15




FN-B Suspicious for Follicular neoplasia Benign (follicular adenoma) 4
FN-M Suspicious for Follicular neoplasia Malignant (follicular carcinoma) 6
FNAC Fine needle aspiration cytology, n number of patients, AUS atypia of undetermined significance, FN Follicular neoplasm, AUS-B atypia of undetermined
significance – benign, AUS-M atypia of undetermined significance – Malignant, FN-B Follicular adenoma, FN-M Follicular carcinoma
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carcinomas tended to be methylated much more fre-
quently than of follicular adenomas, but it did not
reach the level of significance (50 % vs 0 %; p = 0.200).
Discussion
The association between well-differentiated thyroid car-
cinomas and TSHr methylation status was previously
studied using formaldehyde-fixed paraffin-embedded
thyroid tissues or thyroid cell lines [3, 6–9]. However,
its potential diagnostic impact on thyroid FNAC was
not investigated elsewhere. In our study, we found that
a significant number (over half ) of patients with thyroid
nodule showed TSHr methylation using cytological
material. Unsurprisingly, papillary thyroid carcinomas
tended to show more frequent TSHr methylation
compared to benign thyroidal nodules or follicular ad-
enomas. Moreover, we demonstrated a higher fre-
quency of TSHr methylation in follicular carcinomas
than in follicular adenomas, although the difference did
not reach statistical significance possibly due to low
number of studied cases. Regarding the fact that thy-
roid FNAC and Bethesda classification have a major
role in the surgical management of thyroid nodules, the
assessment of TSHr methylation status may be a useful
marker adjunct to the cytological examination, in par-
ticular, aiding to differentiate papillary thyroid carcin-
omas from colloidal nodules, as well as follicular
adenomas from follicular carcinomas. The results of
our study also indicate that the evaluation of TSHr
methylation status has no impact on the cases diag-
nosed as “atypia of undetermined significance” of






of nodule (mean ± SD, mm)
Serum Thyroglobulin
[median, mg/dl (IQR)]
Cases with high (>50 mg/dl)
thyroglobulin (%)
B 50 ± 14 1:15 26 ± 9 47.8 (20.0–160.3) 50
PTC 40 ± 10 4:11 14 ± 8 9.3 (0.2–98.0) 33
AUS 52 ± 13 2:26 22 ± 12 33.0 (1.3–119.0) 36
AUS-B 55 ± 13 1:14 22 ± 13 41 (0.3–135.5) 39
AUS-M 48 ± 13 1:12 23 ± 11 20 (3.1–96.5) 33
FN 54 ± 14 3:7 33 ± 11 16.7 (3.0–66.3) 25
FN-B 50 ± 14 2:2 28 ± 5 8.4 (2.6–32.7) 0
FN-M 57 ± 15 1:5 36 ± 13 35.4 (5.7–159.0) 50
M Male, F Female, IQR Interquartile range, SD Standard deviation
Fig. 2 TSHr methylation status of diagnostic groups
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Bethesda classification. Because the sensitivity and spe-
cificity of TSHr methylation for detecting malignancy is
found to be around 60–65 %, its direct use as a marker
of malignancy is not recommended.
According to study of Smith et al., in which gene-
specific methylation status of TSHr, ECAD, NIS- L,
ATM and DAPC receptors were studied, methylation
rates for NIS-L, ATM, ECAD, and TSHr were higher
in papillary thyroid carcinoma compared to the con-
trol group, including colloidal nodules, follicular ad-
enoma, and non-neoplastic thyroid tissue [6]. TSHr
methylation rate for papillary thyroid carcinoma was
only 34 % (11/32), approximately one third of our
rate in PTC group reaching 90 % in our study. Intri-
guingly, they also observed TSHr methylation in 20 %
(2/10) of follicular adenomas. The results of Xing et al.
[7] are more comparable with our findings: none of
normal thyroid tissue or adenomas had TSHr in the
methylated form, whereas 59 % of papillary thyroid
carcinomas and 47 % of follicular carcinomas showed a
TSHr methylation. Similarly, Dai et al. demonstrated
that 68 % of papillary thyroid carcinomas harbored
TSHr methylation among Chinese population [8].
These differences in the methylation status of TSHr
between our study and the others can be explained on
several grounds. Firstly, cytopathological preparations
we used for the DNA isolation was superior to the
histological material that is formalin-fixed paraffin-
embedded tissue used by the previous studies. Second,
regional differences affecting both genetic and envir-
onmental properties may also account on deviation of
the TSHr methylation status. Field effect may have an
impact on the microenvironment of thyroid tissue and
the development of epigenetic changes, regarding to
the finding that TSHr methylation status of the neo-
plastic nodule with surrounding non-neoplastic thy-
roid tissue was comparable [8]. Lastly, methodology
can lead to slight diversities.
Based on the high rate of TSHr methylation in papil-
lary thyroid carcinoma, some authors investigated the ef-
fect of de-methylating agents in the treatment of thyroid
malignancies. Kim et al. demonstrated 90 % regression
of oncogenetic differentiation and delay in the thyroid
tumor growth in the group treated with 5′-aza-2′deoxy-
nucleotide, a de-methylating agent [9]. Regarding to the
fact that all papillary thyroid carcinomas with metastasis
have shown to bear TSHr methylation in our study, pa-
tients with metastatic disease may become the first can-
didates for such a potential therapy with de-methylating
agents in the future. Smith et al. found that tumors re-
curred less in patients with methylated TSHr; however,
TSHr methylation status in papillary thyroid carcin-
oma needs to be further investigated for its prognostic
value.
Conclusion
According to our study, TSHr methylation status could
be used as a diagnostic test in patients with well differ-
entiated thyroid carcinoma especially in “suspicious for
follicular neoplasia” and “papillary thyroid carcinoma”
groups; however, low sensitivity and specificity for deter-
mination of carcinoma, limits its diagnostic usefulness.
TSHr in the methylated form is always present in meta-
static papillary thyroid carcinomas, therefore TSHr
methylation status may be used as a prognostic factor
and as a potential predictive factor for the treatment
modalities such as de-methylating agents in the future.
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